RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $469
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara has maintained an 'Outperform' rating on Bio-Rad Laboratories and raised the price target from $446 to $469.
October 31, 2024 | 7:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its 'Outperform' rating for Bio-Rad Laboratories and increased the price target from $446 to $469, indicating positive expectations for the company's stock performance.
The increase in the price target from $446 to $469 by RBC Capital suggests a positive outlook for Bio-Rad Laboratories. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100